Amylyx Pharmaceuticals (AMLX) Confirms FDA Approval of RELYVRIO for the Treatment of ALS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amylyx Pharmaceuticals (AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ
September 30, 2022 8:49 AM EDTAmylyx Pharmaceuticals (NASDAQ: AMLX) Sets List Price of $12,500 for 28-Day Supply of ALS Drug Relyvrio -- WSJ
... MoreAfter-Hours Movers 09/29: Nike, Micron Fall Post Earnings
September 29, 2022 5:54 PM EDTAfter-Hours Stock Movers
Rent-A-Center, Inc. (NASDAQ/NGS: RCII) 17% LOWER; lowers third-quarter guidance.
Nike (NYSE: NKE) 10% LOWER; reported Q1 EPS of $0.93, $0.01 better than the analyst estimate of $0.92. Revenue for the quarter came in at $12.7 billion versus the consensus estimate of $12.29... More
Amylyx Pharmaceuticals' (AMLX) Relyvrio Receives Approval from FDA
September 29, 2022 4:34 PM EDT(Updated - September 29, 2022 4:47 PM EDT)
Amylyx Pharmaceuticals' (NASDAQ: AMLX) Relyvrio received approval from the FDA for treatment of amyotrophic lateral sclerosis in adults.
... More